Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 156 participants.
Also called NCT06218342
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 156 participants
- Sponsor
- Registry
-
NCT06218342
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT06218342. Randomized; no masking; primary purpose treatment. Start 2024-02-15 (anticipated); primary completion 2025-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
- Condition
- Type 2 Diabetes
- Condition
- Non-Alcoholic Fatty Liver Disease
- Intervention (Drug)
- Henagliflozin
- Intervention (Other)
- Background medication
- Lead sponsor
- Sir Run Run Shaw Hospital
Record details
- Record id
cardio:ct-nct06218342- Content hash
b71d122dba44a5ed4674a6b9ca662a444876a51efd6a48e7dc809341efa28571